A Phase 4 interventional study of Enoxaparin 40 mg / 0.4 mL Prefilled Syringe and Aspirin 100 mg Oral Tablet, Enteric Coated in Placental Insufficiency and Enoxaparin, sponsored by Les Laboratoires des Médicaments Stériles. Completed at 1 site in Tunisia. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2020-07-02.
Sponsored by Les Laboratoires des Médicaments Stériles · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Assessment of the effectiveness of Enoxaparin, at a preventive dose, combined with Aspirin treatment versus Aspirin only treatment in reducing placental insufficiency in pregnant women.
Randomized, prospective, monocentric, open-label comparative study with two parallel groups (Enoxaparin, at a preventive dose, combined with Aspirin versus Aspirin alone), with the main objective being to evaluate the effectiveness of enoxaparin, at a preventive dose, in reducing placental insufficiency during pregnancy in pregnant women.
24 studies on the registry are indexed under Placental Insufficiency; 7 are open to participants now.
This study's enrollment of 89 is close to the median of 97 across 10 interventional studies indexed under Placental Insufficiency.
Browse Placental Insufficiency studies →Les Laboratoires des Médicaments Stériles is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients going on ASPIRIN 100 mg/day combined with ENOXAPARIN 4000 IU per dat prevention treatment according to randomization: * Administer Aspirin 100 mg Oral Tablet, Enteric Coated once daily * Administer the Enoxaparin preventive dose of 4000 IU as a subcutaneous Enoxaparin 40 mg / 0.4 mL Prefilled Syringe once daily * Start treatment from inclusion visit * Maintain treatment until the day of delivery, or the appearance of a complication (Retroplacental hematoma (RPH), preeclampsia (PE) , In utero fetal death (IUFD), or Intrauterine growth restriction (IUGR) and its complications)
Drug: Enoxaparin 40 mg / 0.4 mL Prefilled Syringe · Drug: Aspirin 100 mg Oral Tablet, Enteric Coated
Patients going on ASPIRIN 100 mg/day prevention treatment alone according to randomization: * Administer only Aspirin 100 mg Oral Tablet, Enteric Coated once daily * Administer orally * Start treatment from inclusion visit * Maintain treatment until 35 Weeks of Amenorrhea (WA)
Drug: Aspirin 100 mg Oral Tablet, Enteric Coated
Drug page: Enoxaparin
Incidence of maternal death
To compare the incidence of maternal death between the two arms of the study.
Time frame: 7 - 42 weeks of amenorrhea
Recurrence rate of preeclampsia
To compare the recurrence rate of preeclampsia between the two arms of the study.
Time frame: 7 - 42 weeks of amenorrhea
Incidence of intrauterine growth restriction (IUGR)
To compare the incidence of IUGR between the two arms of the study.
Time frame: 7 - 42 weeks of amenorrhea
Incidence of retroplacental hematoma (RPH)
To compare the incidence of RPH between the two arms of the study.
Time frame: 7 - 42 weeks of amenorrhea
Incidence of perinatal death
To compare the incidence of perinatal death between the two arms of the study.
Time frame: 7 - 42 weeks of amenorrhea
Incidence of miscarriage
To compare the incidence of miscarriage between the two arms of the study.
Time frame: 13 - 21 weeks of amenorrhea
Incidence of in utero fetal death (IUFD)
To compare the incidence of IUFD between the two arms of the study.
Time frame: 22 weeks of amenorrhea at birth
Incidence of neonatal death
To compare the incidence of neonatal death between the two arms of the study.
Time frame: From birth to 28 days of life
Number of adverse events
To compare the safety of both study products
Time frame: 7 - 42 weeks of amenorrhea
Ran from Oct 2013 to primary completion in Jul 2018, 57 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enoxaparin
Les Laboratoires des Médicaments Stériles